| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
| Targets |
Tripeptide-1 targets the dermis layer of the skin, where it promotes the synthesis of extracellular matrix components including collagen and glycosaminoglycans. It stimulates skin tissue repair and reshapes the biochemical function of the skin, thereby improving skin firmness. The peptide is involved in cellular processes that promote wound healing and tissue regeneration. Its ability to mimic natural peptide sequences facilitates insights into molecular biology and enzymatic activity.
|
|---|---|
| ln Vitro |
In vitro, Tripeptide-1 stimulates collagen production in skin cells. It promotes skin tissue repair and improves skin firmness. The peptide is used in biochemical research to study cellular processes and enzymatic activity. It can directly penetrate the dermis layer to supplement lost collagen, reorganize skin fiber structure, restore skin elasticity, delay cellular aging, and improve fine wrinkles. Specific IC50 values are not reported.
|
| ln Vivo |
Specific in vivo data for Tripeptide-1 are limited. As a cosmetic ingredient, it is applied topically to promote skin rejuvenation and anti-aging effects. The peptide stimulates skin tissue repair, improving skin firmness and reducing wrinkles. It is widely used in cosmetic and skincare products for its beneficial effects on skin health. No clinical trials for therapeutic indications are reported.
|
| Enzyme Assay |
The biological activity of Tripeptide-1 is typically assessed using in vitro cell culture models. Fibroblasts or keratinocytes are cultured and treated with the peptide at various concentrations (e.g., 0.1-100 μg/mL) for 24-72 hours. Collagen synthesis is measured by ELISA or Western blot for collagen types I and III. Cell proliferation is assessed using MTT or BrdU incorporation assays. The peptide is typically dissolved in sterile water or PBS and filter-sterilized before use.
|
| Cell Assay |
For cellular studies, human dermal fibroblasts or keratinocytes are cultured in appropriate media supplemented with 10% FBS at 37°C in 5% CO₂. Cells are treated with Tripeptide-1 at various concentrations for 24-72 hours. Cell viability is assessed using MTT or similar assays. Collagen production is measured by ELISA or immunocytochemistry. Gene expression of collagen and other extracellular matrix proteins is analyzed by qPCR. The peptide has a molecular weight of 400.43 g/mol and a molecular formula of C₁₆H₂₈N₆O₆.
|
| Animal Protocol |
In vivo studies for Tripeptide-1 are conducted in skin models or clinical studies for cosmetic efficacy. Topical formulations containing the peptide are applied to human skin, and effects on skin firmness, wrinkle depth, and hydration are measured using non-invasive instruments (e.g., cutometer, profilometer). Skin biopsies may be taken for histological analysis of collagen content. However, specific published protocols for research use are limited.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for Tripeptide-1 are not reported. As a small peptide, it is expected to have limited systemic absorption when applied topically. The peptide can directly penetrate the dermis layer, suggesting some skin penetration capability. The compound is typically stored at 2-8°C or as a powder at -20°C.
|
| Toxicity/Toxicokinetics |
Tripeptide-1 is naturally present in human blood and saliva and is generally considered safe for topical use in cosmetic products. No significant toxicity has been reported at the concentrations used in cosmetic formulations. As a cosmetic ingredient, it is widely used in anti-aging and skin care products. Comprehensive toxicology studies for systemic administration have not been reported.
|
| Additional Infomation |
Tripeptide-1 (GHK) is a naturally occurring tripeptide that stimulates collagen synthesis and skin tissue repair. It is widely used in anti-aging cosmetics. Molecular formula: C₁₆H₂₈N₆O₆, MW: 400.43. No clinical therapeutic approvals exist. For cosmetic and research use only.
|
| Molecular Formula |
C16H28N6O6
|
|---|---|
| Molecular Weight |
400.44
|
| Exact Mass |
400.207
|
| CAS # |
72957-37-0
|
| Related CAS # |
49557-75-7 (Parent)
|
| PubChem CID |
22214678
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.324 g/cmH3
|
| Boiling Point |
831ºC at 760 mmHg
|
| Flash Point |
456.4ºC
|
| LogP |
0.367
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
28
|
| Complexity |
465
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
NCCCC[C@H](NC([C@@H](NC(CN)=O)CC1=CN=CN1)=O)C(O)=O.CC(O)=O
|
| InChi Key |
MGNUTAFMLGJBGV-ACMTZBLWSA-N
|
| InChi Code |
InChI=1S/C14H24N6O4.C2H4O2/c15-4-2-1-3-10(14(23)24)20-13(22)11(19-12(21)6-16)5-9-7-17-8-18-9;1-2(3)4/h7-8,10-11H,1-6,15-16H2,(H,17,18)(H,19,21)(H,20,22)(H,23,24);1H3,(H,3,4)/t10-,11-;/m0./s1
|
| Chemical Name |
acetic acid;(2S)-6-amino-2-[[(2S)-2-[(2-aminoacetyl)amino]-3-(1H-imidazol-5-yl)propanoyl]amino]hexanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4973 mL | 12.4863 mL | 24.9725 mL | |
| 5 mM | 0.4995 mL | 2.4973 mL | 4.9945 mL | |
| 10 mM | 0.2497 mL | 1.2486 mL | 2.4973 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
